Literature DB >> 19610618

Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach.

Rongshi Li1, Alan Pourpak, Stephan W Morris.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19610618      PMCID： PMC2888655          DOI： 10.1021/jm9002395

Source DB:  PubMed          Journal:  J Med Chem        ISSN： 0022-2623            Impact factor:   7.446


× No keyword cloud information.
  284 in total

1.  Structure and autoregulation of the insulin-like growth factor 1 receptor kinase.

Authors:  S Favelyukis; J H Till; S R Hubbard; W T Miller
Journal:  Nat Struct Biol       Date:  2001-12

Review 2.  Insulin-like growth factor-I receptors and estrogen receptors interact in the promotion of neuronal survival and neuroprotection.

Authors:  L M Garcia-Segura; G P Cardona-Gómez; J A Chowen; I Azcoitia
Journal:  J Neurocytol       Date:  2000 May-Jun

Review 3.  Oncogenic kinase signalling.

Authors:  P Blume-Jensen; T Hunter
Journal:  Nature       Date:  2001-05-17       Impact factor: 49.962

4.  Increased cardiac sympathetic activity and insulin-like growth factor-I formation are associated with physiological hypertrophy in athletes.

Authors:  G G Neri Serneri; M Boddi; P A Modesti; I Cecioni; M Coppo; L Padeletti; A Michelucci; A Colella; G Galanti
Journal:  Circ Res       Date:  2001-11-23       Impact factor: 17.367

5.  Glycogen synthase kinase-3beta regulates presenilin 1 C-terminal fragment levels.

Authors:  F Kirschenbaum; S C Hsu; B Cordell; J V McCarthy
Journal:  J Biol Chem       Date:  2001-06-11       Impact factor: 5.157

Review 6.  Minireview: tissue-specific versus generalized gene targeting of the igf1 and igf1r genes and their roles in insulin-like growth factor physiology.

Authors:  A A Butler; D LeRoith
Journal:  Endocrinology       Date:  2001-05       Impact factor: 4.736

7.  Gene expression of insulin-like growth factors and receptors in neoplastic prostate tissues: correlation with clinico-pathological parameters.

Authors:  J A Figueroa; S De Raad; V O Speights; J J Rinehart
Journal:  Cancer Invest       Date:  2001       Impact factor: 2.176

Review 8.  The ins(ide) and out(side) of dolichyl phosphate biosynthesis and recycling in the endoplasmic reticulum.

Authors:  B Schenk; F Fernandez; C J Waechter
Journal:  Glycobiology       Date:  2001-05       Impact factor: 4.313

Review 9.  Current therapies and emerging targets for the treatment of diabetes.

Authors:  A S Wagman; J M Nuss
Journal:  Curr Pharm Des       Date:  2001-04       Impact factor: 3.116

10.  ATM-dependent expression of the insulin-like growth factor-I receptor in a pathway regulating radiation response.

Authors:  S Peretz; R Jensen; R Baserga; P M Glazer
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-06       Impact factor: 11.205
View more
  42 in total

1.  Genomic and molecular characterization of malignant peripheral nerve sheath tumor identifies the IGF1R pathway as a primary target for treatment.

Authors:  Jilong Yang; Antti Ylipää; Yan Sun; Hong Zheng; Kexin Chen; Matti Nykter; Jonathan Trent; Nancy Ratner; Dina C Lev; Wei Zhang
Journal:  Clin Cancer Res       Date:  2011-10-31       Impact factor: 12.531

2.  Therapeutic destruction of insulin receptor substrates for cancer treatment.

Authors:  Hadas Reuveni; Efrat Flashner-Abramson; Lilach Steiner; Kirill Makedonski; Renduo Song; Alexei Shir; Meenhard Herlyn; Menashe Bar-Eli; Alexander Levitzki
Journal:  Cancer Res       Date:  2013-05-07       Impact factor: 12.701

3.  Association of insulin-like growth factor-I receptor polymorphism with colorectal cancer development.

Authors:  Noyko S Stanilov; Iliya A Karakolev; Tashko S Deliysky; Jovcho P Jovchev; Spaska A Stanilova
Journal:  Mol Biol Rep       Date:  2014-09-05       Impact factor: 2.316

4.  p53 overexpression increases chemosensitivity in multidrug-resistant osteosarcoma cell lines.

Authors:  Shunan Ye; Jacson Shen; Edwin Choy; Cao Yang; Henry Mankin; Francis Hornicek; Zhenfeng Duan
Journal:  Cancer Chemother Pharmacol       Date:  2015-12-23       Impact factor: 3.333

5.  GPER1-mediated IGFBP-1 induction modulates IGF-1-dependent signaling in tamoxifen-treated breast cancer cells.

Authors:  Ali Vaziri-Gohar; Kevin D Houston
Journal:  Mol Cell Endocrinol       Date:  2015-12-13       Impact factor: 4.102

6.  Discovery of an Orally Efficacious Imidazo[5,1-f][1,2,4]triazine Dual Inhibitor of IGF-1R and IR.

Authors:  Meizhong Jin; Prafulla C Gokhale; Andy Cooke; Kenneth Foreman; Elizabeth Buck; Earl W May; Lixin Feng; Mark A Bittner; Mridula Kadalbajoo; Darla Landfair; Kam W Siu; Kathryn M Stolz; Douglas S Werner; Radoslaw S Laufer; An-Hu Li; Hanqing Dong; Arno G Steinig; Andrew Kleinberg; Yan Yao; Jonathan A Pachter; Robert Wild; Mark J Mulvihill
Journal:  ACS Med Chem Lett       Date:  2010-08-30       Impact factor: 4.345

7.  Discovery of novel insulin-like growth factor-1 receptor inhibitors with unique time-dependent binding kinetics.

Authors:  Meizhong Jin; Brenda A Petronella; Andy Cooke; Mridula Kadalbajoo; Kam W Siu; Andrew Kleinberg; Earl W May; Prafulla C Gokhale; Ryan Schulz; Jennifer Kahler; Mark A Bittner; Kenneth Foreman; Jonathan A Pachter; Robert Wild; David Epstein; Mark J Mulvihill
Journal:  ACS Med Chem Lett       Date:  2013-05-23       Impact factor: 4.345

8.  Mutational analysis of the insulin-like growth factor 1 receptor tyrosine kinase domain in non-small cell lung cancer patients.

Authors:  Kathy Gately; Lydia Forde; Stephen Gray; Derek Morris; Aidan Corvin; Prerna Tewari; Kenneth O'Byrne
Journal:  Mol Clin Oncol       Date:  2015-06-11

9.  LMP1 promotes expression of insulin-like growth factor 1 (IGF1) to selectively activate IGF1 receptor and drive cell proliferation.

Authors:  Kathryn Tworkoski; Nancy Raab-Traub
Journal:  J Virol       Date:  2014-12-17       Impact factor: 5.103

10.  Do MCF7 cells cope with metformin treatment under energetic stress in low glucose conditions?

Authors:  Irem Dogan Turacli; Haldun Umudum; Arzu Pampal; Tuba Candar; Lara Kavasoglu; Yaren Sari
Journal:  Mol Biol Rep       Date:  2018-02-03       Impact factor: 2.316
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.